AC Immune SA (ACIU) vs Relmada Therapeutics (RLMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Relmada Therapeutics (RLMD) has outperformed AC Immune SA (ACIU) over the past year, gaining 54.2% versus a loss of 17.6%. Over five years, ACIU leads with a -60.4% price change compared with -87.0% for RLMD. Relmada Therapeutics is the larger company by market cap ($330.7 million vs $237.6 million), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACIU | RLMD |
|---|---|---|
| Share price | $2.39 | $3.10 |
| Market cap | $237.63M | $330.68M |
| 1-day change | -2.45% | -3.13% |
| YTD return | -23.89% | -35.82% |
| 1-year return | -17.59% | +54.23% |
| 5-year return | -60.36% | -86.99% |
| Forward P/E | 3.98 | — |
| EPS (TTM) | $-0.54 | $-0.91 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-57.39M |
| 52-week high | $4.00 | $8.00 |
| 52-week low | $2.10 | $1.97 |
| Distance from 52-week high | -40.25% | -61.25% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +261.51% | +246.77% |
| Average volume | 198.18K | 1.30M |
| Shares outstanding | 99.43M | 106.67M |
| Employees | 90 | 17 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RLMD has outperformed ACIU by 71.8 percentage points over the past year.
About AC Immune SA
ACIU stock →AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Healthcare · Biotechnology · 90 employees
About Relmada Therapeutics
RLMD stock →Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States.
Healthcare · Biotechnology · 17 employees
ACIU vs RLMD FAQ
Which is bigger, AC Immune SA or Relmada Therapeutics?
Relmada Therapeutics (RLMD) is larger, with a market capitalization of $330.68M compared with $237.63M for AC Immune SA (ACIU).
Which stock has performed better over the past year, ACIU or RLMD?
RLMD returned +54.23% over the past 12 months, compared with -17.59% for ACIU (price return, excluding dividends). Past performance does not predict future results.
Are AC Immune SA and Relmada Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.